Søren Bregenholt

  • Independent in relation to the Company and its management: No
  • Independent in relation to major shareholders: Yes
  • Holdings in Alligator: 1,103,019 shares, 500,000 warrants in program TO 2022/2025 I, 1,200,000 warrants in program TO 2023/2026 I, 900,000 warrants in program TO 2024/2027 I and 194,666 warrants in program TO 9.
  • Other current positions: Chairman of Medicon Valley Alliance, Chairman of A Bioscience Incentive AB and Atlas Therapeutics AB, and Board member of Oblique Therapeutics AB (publ).

Søren Bregenholt – born 1971, Chief Executive Officer – holds a PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. Søren has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen and Macrophage Pharma. He has negotiated and operationalized numerous licensing, collaboration and co-development agreements. Employed since June 2021 and member of the Management Team since 2021.

Updated 2024-05-21